Skip to main content
ORIGINAL RESEARCH

Assessing Rates and Predictors of Tachyphylaxis During the Prevention of Recurrent Episodes of Depression With Venlafaxine ER for Two Years (PREVENT) Study

Psychopharmacology Bulletin 42(3): 5-20, 2009/08/24; https://doi.org/10.64719/pb.4086

Abstract

Background: Antidepressant tachyphylaxis describes the return of apathetic depressive symptoms, such as fatigue and decreased motivation, despite continued use of a previously effective treatment. Methods: Data were collected from a multiphase, double-blind, placebo-controlled study that assessed the efficacy of venlafaxine extended release (ER) during 2 sequential 1-year maintenance phases (A and B) in patients with recurrent major depressive disorder (MDD). The primary outcome was the cumulative probability of tachyphylaxis in patients receiving venlafaxine ER, fluoxetine, or placebo. Tachyphylaxis was defined as Rothschild Scale for Antidepressant Tachyphylaxis (RSAT) score ≥ 7 in patients with prior satisfactory therapeutic response. A Kaplan–Meier

Access This Article

Choose an access option below to view the full article.

Subscriber Access

If you or your institution has a subscription, log in to access this article.

Log In

Purchase Article

Buy single-article access with a one-time purchase.

$30.00
Add to Cart

How to Cite

Anthony J. Rothschild, Boadie W. Dunlop, David L. Dunner, Edward S. Friedman, Alan Gelenberg, Peter Holland, James H. Kocsis, Susan G. Kornstein, Richard Shelton, Madhukar H. Trivedi, John M. Zajecka, Corey Goldstein, Michael E. Thase, Ron Pedersen, Martin B. Keller. Assessing Rates and Predictors of Tachyphylaxis During the Prevention of Recurrent Episodes of Depression With Venlafaxine ER for Two Years (PREVENT) Study. Psychopharmacology Bulletin. 2009/08/24; 42(3):5-20. https://doi.org/10.64719/pb.4086